Tenon(R) Medical Issues Shareholder Letter and Provides Preliminary Revenue for the Fourth Quarter and Full Year 2025

Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over year.

Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year.

LOS GATOS, CA / ACCESS Newswire / January 28, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today issued a letter to shareholders from Steve Foster, President and Chief Executive Officer.

Dear Fellow Shareholders,

2025 was marked by strong commercial execution as we advanced innovation and expanded our differentiated solutions in the marketplace. We delivered both sequential and year over year revenue growth and strengthened our liquidity position, placing Tenon on firmer financial footing heading into 2026. Our expanding product portfolio-driven by the acquisition of sacroiliac joint-specific assets from SiVantage and the recent FDA clearance and commercialization of the SImmetry+ SI Joint Fusion System-positions us to scale revenue and address a broader range of sacro-pelvic fixation and fusion needs. Entering 2026, we have laid a strong foundation for sustained growth through portfolio diversification, commercial expansion, and improved operational alignment.

Preliminary Fourth Quarter & Full Year 2025 Revenue

Following record revenue growth in the third quarter, the Company is reporting preliminary, unaudited fourth quarter revenue of approximately $1.45 to $1.48 million for the period ended December 31, 2025, representing approximately 90% growth compared to the fourth quarter ended December 31, 2024. Preliminary unaudited full year 2025 revenue is expected to be approximately $3.91 to $3.94 million, representing approximately 20% year over year growth. Revenue acceleration in the second half of 2025 was driven by strong procedural volume momentum, which we expect to continue into 2026. This momentum was primarily fueled by adoption among new physician users of both the Catamaran and SImmetry+ systems.

These revenue results are preliminary and subject to adjustment upon completion of customary year-end audit procedures. The Company expects to report fourth-quarter and full-year 2025 financial results in March 2026.

Major Company Milestones in 2025

Throughout 2025, our primary focus was advancing product innovation and generating robust clinical outcomes to transform Tenon into a multi-product, multi-approach company. Today, we offer physicians differentiated technologies that support customized treatment strategies for patients with sacro-pelvic disorders, utilizing novel, true fusion solutions backed by compelling clinical evidence. Key milestones in 2025 include:

Schreibe Deinen Kommentar